Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/2159-8290.CD-16-0860 http://scihub22266oqcxt.onion/10.1158/2159-8290.CD-16-0860 C5300099!5300099 !28003236     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28003236 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28003236 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Cancer+Discov 2017 ; 7 (1 ): 20-37 Nephropedia Template TP {{tp|p=28003236 |t=2017. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors |pdf=|usr=}}{{28003236 }} gab.com Text Targeting DNA Repair in Cancer: Beyond PARP Inhibitors JO: Cancer Discov http://www.kidney.de/pget.php?&tw=1&pmid=28003236 #FOAvip Germline aberrations in critical DNA-repair and DNA damage-response (DDR) genes cause cancer predisposition, whereas various tumors harbor somatic mutations causing defective DDR/DNA repair. The concept of synthetic lethality can be exploited in such malignancies, as exemplified by approval of poly(ADP-ribose) polymerase inhibitors for treating BRCA1/2-mutated ovarian cancers. Herein, we detail how cellular DDR processes engage various proteins that sense DNA damage, initiate signaling pathways to promote cell-cycle checkpoint activation, trigger apoptosis, and coordinate DNA repair. We focus on novel therapeutic strategies targeting promising DDR targets and discuss challenges of patient selection and the development of rational drug combinations. SIGNIFICANCE: Various inhibitors of DDR components are in preclinical and clinical development. A thorough understanding of DDR pathway complexities must now be combined with strategies and lessons learned from the successful registration of PARP inhibitors in order to fully exploit the potential of DDR inhibitors and to ensure their long-term clinical success. Cancer Discov; 7(1); 20-37. ©2016 AACR. Twit Text FOAVip Targeting DNA Repair in Cancer: Beyond PARP Inhibitors ????Cancer Discov http://www.kidney.de/pget.php?&tw=1&pmid=28003236 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28003236 #FOAvip English Wikipedia <ref>{{Cite pmid|28003236 }}</ref> Targeting DNA Repair in Cancer: Beyond PARP Inhibitors #MMPMID28003236 Brown JS ; O'Carrigan B ; Jackson SP ; Yap TA Cancer Discov 2017[Jan]; 7 (1 ): 20-37 PMID28003236 show ga Germline aberrations in critical DNA-repair and DNA damage-response (DDR) genes cause cancer predisposition, whereas various tumors harbor somatic mutations causing defective DDR/DNA repair. The concept of synthetic lethality can be exploited in such malignancies, as exemplified by approval of poly(ADP-ribose) polymerase inhibitors for treating BRCA1/2-mutated ovarian cancers. Herein, we detail how cellular DDR processes engage various proteins that sense DNA damage, initiate signaling pathways to promote cell-cycle checkpoint activation, trigger apoptosis, and coordinate DNA repair. We focus on novel therapeutic strategies targeting promising DDR targets and discuss challenges of patient selection and the development of rational drug combinations. SIGNIFICANCE: Various inhibitors of DDR components are in preclinical and clinical development. A thorough understanding of DDR pathway complexities must now be combined with strategies and lessons learned from the successful registration of PARP inhibitors in order to fully exploit the potential of DDR inhibitors and to ensure their long-term clinical success. Cancer Discov; 7(1); 20-37. ©2016 AACR. |Animals [MESH] |Antineoplastic Agents/pharmacology/*therapeutic use [MESH] |DNA Repair/*drug effects [MESH] |Drug Screening Assays, Antitumor [MESH] |Genetic Predisposition to Disease [MESH] |Humans [MESH] |Mutation [MESH] |Neoplasms/*drug therapy/genetics [MESH]Targeting DNA Repair in Cancer: Beyond PARP Inhibitors (epmc).pdf DeepDyve Pubget Overpricing